Anticonvulsants Market By Disease Treatment 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Anticonvulsants Market
Anticonvulsants Market: By Disease Treatment (Epilepsy, Migraine, Fibromyalgia, Neuropathic pain, Anxiety, Bipolar disorder); By Drugs Type(AMPA, Triazine, Benzodiazepine, Dibenzazepine, Barbiturate and Others) and By Geography - Forecast (2016-2021)
Report Code : HCR 0154
Updated Date: 22 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Anticonvulsants – Market Overview
2. Executive Summary
3. Anticonvulsants Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Anticonvulsants – Market Forces
   4.1. Drivers
      4.1.1. Increasing global awareness about the availability of anticonvulsants
   4.2. Restraints
      4.2.1. Large scale availability of cost effective generic drugs
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Anticonvulsants Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Anticonvulsants Market, By Treatment
   6.1. Epilepsy
   6.2. Migraine
   6.3. Fibromyalgia
   6.4. Neuropathic pain
   6.5. Anxiety
   6.6. Bipolar disorder
7. Anticonvulsants Market, By Drugs Type
   7.1. AMPA
   7.2. Barbiturate
   7.3. Benzodiazepine
   7.4. Carbamate anticonvulsants
   7.5. Carbonic anhydrase inhibitor
   7.6. Dibenzazepine
   7.7. Triazine
   7.8. Others
8. Anticonvulsants Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Anticonvulsants – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles
   10.1. Pfizer inc. 
      10.1.1.  Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Novartis International AG 
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Abbott Laboratories   
      10.3.1.  Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. UCB   
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. Johnson & Johnson
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. GlaxoSmithKline Pharmaceuticals Ltd
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Sunovion Pharmaceuticals, Inc
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Eisai Pharmaceuticals India Pvt. Ltd
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. Bial
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. Otsuka Pharmaceutical
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Anticonvulsants (also commonly known as antiepileptic drugs or as antiseizure drugs) are drugs that are used in the prevention or reduction of the severity and frequency of seizures in various types of epilepsy. Epilepsy can be defined as a neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions, associated with abnormal electrical activity in the brain. There several different types of anticonvulsants which may act on different receptors in the brain and have different modes of action.

This report identifies the anticonvulsants market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to anticonvulsants market.

Anticonvulsants Market

Globally North America dominated the market for anticonvulsants in 2015 due to highly developed healthcare infrastructure, high level of awareness, high healthcare spending on epilepsy, and availability of skilled professionals for treating epilepsy. North America was followed by Europe and Asia-Pacific as the second and third largest markets respectively for anticonvulsants in 2015. Demand for anticonvulsants in Asia-Pacific is expected to witness fastest growth in the near future due to constantly increasing medical tourism in the countries such as China, India and Japan. Also increasing investment by the regional governments in the field of medical infrastructure is also expected to result in increased demand for anticonvulsants in the region.

This report on global anticonvulsants is segmented on the basis of various types of anticonvulsants, treated disease and market size in various geographical regions.
  • On the basis of types of anticonvulsants this report classified as follows covering all major types of anticonvulsants as follows: AMPA, Barbiturate, Benzodiazepine, Carbamate anticonvulsants, Carbonic anhydrase inhibitor, Dibenzazepine, Triazine and Others
  • On the basis of disease treated, anticonvulsants market is segmented as follows: Epilepsy, Migraine, Fibromyalgia, Neuropathic pain, Anxiety and Bipolar disorder
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for anticonvulsants in each of the region.

Sample Companies Profiled in this Report are: 

  • Pfizer inc. 
  • Novartis International AG 
  • Abbott Laboratories  
  • UCB   
  • Johnson & Johnson
  • GlaxoSmithKline Pharmaceuticals Ltd
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports